The content on this site is intended for healthcare professionals only
Brain metastases from lung cancer are the most prevalent type with high numbers of patients developing brain metastases each year. Dr Lucio Crinò from University Hospital of Perugia, Italy discusses the recent analysis of Crizotinib data on brain metastases in lung cancer patients. The standard of care for these patients is traditional surgery, chemotherapy, or radiotherapy with Gamma Knife. Dr Crinò looks at the molecular characteristics of the new targeted treatments such as Crizotinib, and the implications for overall survival and quality of life in this patient population.
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
ESMO 2024: Highlights and analysis
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours
ESMO 2024: Latest in EGFR mutated NSCLC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Uncommon genetic aberrations NTRK, RET, NRG
